# TRUST-P11 — La Roche-Posay Same-Formulation PA Source Recovery Boundary v1

## Status

`NO_ADMISSIBLE_SAME_FORMULATION_DIRECT_PA_LABEL_FOUND`

TRUST-P11 freezes the negative admission boundary for `uva_label` on the current KR La Roche-Posay Anthelios Sun Fluid subject. This phase performs **zero Production Product Fact writes**.

## Authority

- source main: `ad7a8ce3ae46abed433e2ff2544e9bfd2f087007`
- upstream P9 source-recovery artifact: `evidence/product-fact-subject-coverage-v1/trust-p9-lrp-first-party-fact-source-recovery-v1.json`
- upstream P10 Production execution artifact: `evidence/product-fact-adoption-v1/trust-p10-lrp-recovered-spf-hosted-adoption-execution-v1.json`
- Production project: `bygrczggxfuisupcevaz`
- product: `9983f167-24e7-4223-bd86-446ce6ced31b`
- current subject: `614db853-7865-408b-8f40-a4dcfe6a2ea5`
- research timestamp: `2026-09-11T05:56:47.061232+09:00`
- source observation digest: `a15f1b73a2fa6a202d20e7e2a45697209df517219dc9ec023b61ad0ace4d7bf8`

## Admission rule

All of the following are required before `uva_label=PA++++` can be admitted for the current KR subject:

1. first-party source;
2. same formulation as the P9-resolved current KR subject (`C227022/1` bridge / exact ordered 22-ingredient equivalence);
3. direct `PA++++` declaration;
4. product-specific evidence suitable for `uva_label`.

`UVA-PF 46 → PA++++` conversion remains prohibited.

Although the current registry contains `UVA-PF-declared` as a distinct allowed enum value, TRUST-P11 does **not** substitute that enum for the direct `PA++++` recovery required by the existing P9 adjudication. This phase does not widen the semantic target.

## Same-formulation first-party observations

### La Roche-Posay Korea

The current KR 50 ml product and its 22-item ingredient disclosure remain the identity authority. The page identifies UV-blocking functionality but does not directly expose `PA++++` in the reviewed machine-readable product body.

Disposition: `BLOCKED_NO_DIRECT_PA_LABEL`.

### La Roche-Posay Australia

The official Anthelios Invisible Fluid SPF 50+ 50 ml page exposes formula code `C227022/1`, the same 22-item INCI formulation bridge, and very high UVA/UVB protection wording. It does not directly declare `PA++++`.

Disposition: `BLOCKED_NO_DIRECT_PA_LABEL`.

### La Roche-Posay Chile

The official page exposes `C227022/1`, the same 22-item INCI formulation, and `FPS 50+ / UVA-FP 46`. It does not directly declare `PA++++`.

Disposition: `BLOCKED_UVA_PF_ONLY`.

### La Roche-Posay Slovenia

The official page exposes `C227022/1`, the same 22-item INCI formulation, and `SPF50+ / UVA-PF 46`. It does not directly declare `PA++++`.

Disposition: `BLOCKED_UVA_PF_ONLY`.

Result: **4 same-formulation first-party sources reviewed / 0 direct PA++++ hits**.

## PA-bearing first-party candidates rejected

The reviewed La Roche-Posay Japan `Anthelios XL Fluid` page directly exposes `SPF50+・PA++++` and 50 ml, but its formulation is materially different from the current KR/P9 formula. Examples present in the Japan formula but absent from the KR formula include `DIMETHICONE`, `ISOHEXADECANE`, and `OCTOCRYLENE`; examples present in KR but absent from that Japan formula include `ISOPROPYL MYRISTATE` and `ETHYLHEXYL SALICYLATE`.

The reviewed Hong Kong, Taiwan, and Thailand first-party pages directly expose `PA++++`, but they are the newer `UVMUNE 400 / Mexoryl 400` generation rather than the P9 `C227022/1` formulation. They are rejected as formulation-generation mismatches.

A Hwahae listing was observed as third-party corroboration for an Anthelios Invisible Fluid `SPF50+/PA++++` listing with 22 ingredients. It is intentionally excluded from positive support because TRUST-P11 requires first-party authority.

Result: **4 first-party PA-bearing candidates rejected for formulation mismatch / 0 accepted positive UVA support**.

## Fresh Production boundary

Fresh readback at `2026-09-11T05:55:35.813271+09:00` remains:

`Subjects 20 / Sources 20 / Bindings 20 / Evidence 48 / Fact Instances 48 / Review Assignments 48 / Confirmations 48 / Current 48`

Evidence Links remain `48`.

Target product remains:

`Subject 1 / SPF Current 1 / UVA Current 0`

TRUST-P11 performs no Subject, Source, Binding, Evidence, Review, Confirmation, Current, schema, RPC, Registry, recommendation, or ranking mutation.

## Decision

`uva_label = FACT_SOURCE_RECOVERY_REQUIRED`

Eligible next action is **source recovery only**. A Production UVA write remains unauthorized until a same-formulation first-party source directly declares the required PA label for the current KR subject.

```text
SAME_FORMULA_FIRST_PARTY_SOURCES_REVIEWED = 4
SAME_FORMULA_DIRECT_PA_HITS = 0
REJECTED_FIRST_PARTY_PA_CANDIDATES = 4
ACCEPTED_POSITIVE_UVA_SUPPORT = 0
UVA_LABEL_WRITE_AUTHORIZED = NO
UVA_PF_TO_PA_CONVERSION = NO
UVA_PF_DECLARED_SUBSTITUTION = NO
PRODUCTION_PRODUCT_FACT_WRITES = 0
DIRECT_PRODUCT_FACT_DML = 0
```
